These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2243 related articles for article (PubMed ID: 7852647)

  • 1. Novel experimental approaches to melanoma diagnosis and therapy.
    Hearing VJ; Gersten DM; Shrayer D; Law LW
    J Dermatol; 1994 Nov; 21(11):860-9. PubMed ID: 7852647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of the growth of human melanoma metastases in nude mice by melanoma-specific murine monoclonal antibody.
    Abdel-Wahab ZA; Darrow TL; Vervaert CE; Giannopoulou AA; Li W; Seigler HF
    Surg Oncol; 1992 Apr; 1(2):115-25. PubMed ID: 1341242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pre-clinical models for immunotherapy of melanoma.
    Reisfeld RA
    Prog Clin Biol Res; 1989; 288():183-93. PubMed ID: 2654950
    [No Abstract]   [Full Text] [Related]  

  • 4. A new mouse model of experimental melanoma for vaccine and lymphokine therapy.
    Shrayer DP; Bogaars H; Wolf SF; Hearing VJ; Wanebo HJ
    Int J Oncol; 1998 Aug; 13(2):361-74. PubMed ID: 9664134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytokine-based therapy for melanoma: pre-clinical studies.
    Shurin MR; Kirkwood JM; Esche C
    Forum (Genova); 2000; 10(3):204-26. PubMed ID: 11007930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy as an adjuvant therapy in the management of advanced, surgically resected, melanoma.
    Kalani AD; Jack A; Montenegro G; Degliuomini J; Wallack MK
    G Ital Dermatol Venereol; 2008 Feb; 143(1):59-70. PubMed ID: 18833052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Next generation of immunotherapy for melanoma.
    Kirkwood JM; Tarhini AA; Panelli MC; Moschos SJ; Zarour HM; Butterfield LH; Gogas HJ
    J Clin Oncol; 2008 Jul; 26(20):3445-55. PubMed ID: 18612161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New vaccine approach targets melanoma.
    Schub T
    Lab Anim (NY); 2004 Sep; 33(8):9. PubMed ID: 15334096
    [No Abstract]   [Full Text] [Related]  

  • 9. Genetically modified murine adipose-derived mesenchymal stem cells producing interleukin-2 favor B16F10 melanoma cell proliferation.
    Bahrambeigi V; Ahmadi N; Salehi R; Javanmard SH
    Immunol Invest; 2015; 44(3):216-36. PubMed ID: 25565576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation.
    Xu D; Gu P; Pan PY; Li Q; Sato AI; Chen SH
    Int J Cancer; 2004 Apr; 109(4):499-506. PubMed ID: 14991570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of anti-B16 melanoma monoclonal antibody on established murine B16 melanoma liver metastases.
    Eisenthal A; Lafreniere R; Lefor AT; Rosenberg SA
    Cancer Res; 1987 Jun; 47(11):2771-6. PubMed ID: 3494504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Further studies of the therapeutic effects of murine melanoma-specific monoclonal antibodies.
    Law LW; Vieira WD; Hearing VJ; Gersten DM
    Biochim Biophys Acta; 1994 Apr; 1226(1):105-9. PubMed ID: 7908833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple antibodies targeting tumor-specific mutations redirect immune cells to inhibit tumor growth and increase survival in experimental animal models.
    Shukla GS; Pero SC; Sun Y-; Mei L; Zhang F; Sholler G; Krag DN
    Clin Transl Oncol; 2020 Jul; 22(7):1094-1104. PubMed ID: 31732916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy for the management of advanced melanoma: the next steps.
    Zikich D; Schachter J; Besser MJ
    Am J Clin Dermatol; 2013 Aug; 14(4):261-72. PubMed ID: 23516145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic efficacy of antigen-specific vaccination and toll-like receptor stimulation against established transplanted and autochthonous melanoma in mice.
    Tormo D; Ferrer A; Bosch P; Gaffal E; Basner-Tschakarjan E; Wenzel J; Tüting T
    Cancer Res; 2006 May; 66(10):5427-35. PubMed ID: 16707471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy of malignant melanoma.
    Oratz R; Bystryn JC
    Dermatol Clin; 1991 Oct; 9(4):669-82. PubMed ID: 1718648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Melanoma: the development of immunoconjugates from a preclinical viewpoint.
    Beaumier PL; Morgan AC; Woodhouse CS; Marchitto KS
    Immunol Ser; 1990; 53():297-316. PubMed ID: 2100562
    [No Abstract]   [Full Text] [Related]  

  • 18. Type I-polarized BRAF-pulsed dendritic cells induce antigen-specific CD8+ T cells that impact BRAF-mutant murine melanoma.
    Cintolo JA; Datta J; Xu S; Gupta M; Somasundaram R; Czerniecki BJ
    Melanoma Res; 2016 Feb; 26(1):1-11. PubMed ID: 26451873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nude mouse model to study passive humoral immunotherapy directed against B16 F10 murine melanoma.
    Shrayer D; Bogaars H; Gersten D; Hearing V; Maizel A; Wanebo H
    J Surg Oncol; 1994 Sep; 57(1):50-6. PubMed ID: 8065154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential chemoimmunotherapy with cisplatin, interferon-beta and interleukin-2 inhibits the growth of B16-F1 melanoma in syngeneic mice.
    Kubo H; Matsumoto K; Funahashi M; Takagi H; Kitajima Y; Taniguchi S; Saida T
    Melanoma Res; 2000 Jun; 10(3):223-9. PubMed ID: 10890375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 113.